Sun Pharma Advanced Research Company Limited SPARC NSEPHARMA
Company Overview
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 116.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 112.0%.
Net profit has compounded at 265.9% per year over the last five years.
Revenue has grown at a 98.9% CAGR over the past five years.
Trades at a P/E of 5.3, below the sector median of 40.0.
Maintains a net profit margin of 82.7%.
Recent Developments
- Mar 2026 Revenue of ₹1,879.17 Cr (+2518.3% YoY); net profit ₹1,553.20 Cr.
- Trailing 12 Months Year-on-year growth — revenue +2518.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 98.9%, profit CAGR 265.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 98.91% |
| 1 Year: | 2,518.32% |
Compounded Profit Growth
| 5 Years: | 265.94% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +63.31% |
| 6 Months: | +88.38% |
| 3 Months: | +72.15% |
| 1 Month: | +6.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.86 · Neutral
P/E of 5.32 is below the sector median of 39.97 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 116.0%.
- Healthy ROCE of 112.0%.
- Excellent profit margin of 82.7%.
- Compounding revenue at 98.9% over 5 years.
- Profit CAGR of 265.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPARC Sun Pharma Advanced Research Company Limited NSEPHARMA | 254.80 | 5.32 | ₹8,268.81 Cr | 0.00% | 112.03% | 116.01% | 98.91% | 265.94% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.00 Cr | 24.00 Cr | 21.00 Cr | 14.00 Cr | 17.00 Cr | 17.00 Cr | 13.00 Cr | - | 27.19 Cr | 9.64 Cr | 7.86 Cr | 8.45 Cr | 1,853.22 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 17.18 Cr | 10.67 Cr | 14.11 Cr | 13.48 Cr | 8.00 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 10.01 Cr | -1.03 Cr | -6.25 Cr | -5.03 Cr | 1,845.22 Cr |
| Operating Expenses | 137.00 Cr | 126.00 Cr | 113.00 Cr | 116.00 Cr | 122.00 Cr | 110.00 Cr | 116.00 Cr | - | 66.14 Cr | 53.73 Cr | 62.03 Cr | 54.18 Cr | 74.42 Cr |
| Operating Income | -93.00 Cr | -105.00 Cr | -94.00 Cr | -106.00 Cr | -109.00 Cr | -96.00 Cr | -106.00 Cr | - | -56.13 Cr | -54.76 Cr | -68.28 Cr | -59.21 Cr | 1,770.80 Cr |
| EBITDA | -90.00 Cr | -102.00 Cr | -91.00 Cr | -103.00 Cr | -106.00 Cr | -93.00 Cr | -103.00 Cr | - | -53.18 Cr | -42.94 Cr | -65.71 Cr | -69.00 Cr | 1,775.00 Cr |
| Interest Expense | 0 | 0 | 0 | 0 | 1.00 Cr | 1.00 Cr | 1.00 Cr | - | 4.54 Cr | 6.19 Cr | 7.52 Cr | 8.78 Cr | 11.64 Cr |
| Pretax Income | -82.00 Cr | -95.00 Cr | -86.00 Cr | -100.00 Cr | -105.00 Cr | -96.00 Cr | -107.00 Cr | - | -60.67 Cr | -51.81 Cr | -75.79 Cr | -80.35 Cr | 1,760.96 Cr |
| Tax Provision | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | -90.00 L | 6.00 L | 6.00 L | 7.00 L | -38.00 L |
| Net Income | -82.00 Cr | -95.00 Cr | -86.00 Cr | -100.00 Cr | -106.00 Cr | -96.00 Cr | -107.00 Cr | - | -59.77 Cr | -51.87 Cr | -75.85 Cr | -80.42 Cr | 1,761.34 Cr |
| Diluted EPS | -2.53 | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | - | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 238.78 Cr | 75.55 Cr | 71.77 Cr | 1,879.17 Cr |
| Cost of Revenue | - | 176.74 Cr | 135.79 Cr | 104.45 Cr | 46.26 Cr |
| Gross Profit | - | 62.04 Cr | -60.24 Cr | -32.68 Cr | 1,832.91 Cr |
| Operating Expenses | - | 285.69 Cr | 351.26 Cr | 302.85 Cr | 244.36 Cr |
| Operating Income | - | -223.64 Cr | -411.50 Cr | -335.53 Cr | 1,588.55 Cr |
| EBITDA | - | -203.18 Cr | -373.13 Cr | -321.35 Cr | 1,597.35 Cr |
| Interest Expense | - | 7.63 Cr | 1.19 Cr | 9.04 Cr | 34.13 Cr |
| Pretax Income | - | -222.58 Cr | -386.83 Cr | -342.78 Cr | 1,553.01 Cr |
| Tax Provision | - | 0 | 38.20 L | -27.00 L | -19.00 L |
| Net Income | - | -222.58 Cr | -387.21 Cr | -342.51 Cr | 1,553.20 Cr |
| Diluted EPS | - | -7.82 | -11.93 | -10.55 | 47.86 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 830.13 Cr | 515.04 Cr | 335.53 Cr | 2,170.86 Cr |
| Current Assets | - | 454.96 Cr | 269.39 Cr | 26.20 Cr | 1,862.42 Cr |
| Cash & Equivalents | - | 58.36 L | 5.33 Cr | 1.96 Cr | 1.16 Cr |
| Inventory | - | - | - | - | - |
| Receivables | - | 32.71 Cr | 15.53 Cr | 16.06 Cr | 8.27 Cr |
| Total Liabilities | - | 317.35 Cr | 389.29 Cr | 552.48 Cr | 832.04 Cr |
| Current Liabilities | - | 178.95 Cr | 265.06 Cr | 374.24 Cr | 754.09 Cr |
| Long Term Debt | 0 | - | 0 | 100.00 Cr | 0 |
| Total Debt | - | 15.68 Cr | 57.66 Cr | 265.13 Cr | 559.31 Cr |
| Total Equity | - | 512.78 Cr | 125.76 Cr | -216.95 Cr | 1,338.82 Cr |
| Shares Outstanding | - | 32.45 Cr | 32.45 Cr | 32.45 Cr | 32.45 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -69.12 Cr | -429.19 Cr | -360.29 Cr | -238.77 Cr |
| Investing Cash Flow | - | -548.28 Cr | 391.53 Cr | 157.66 Cr | -23.50 Cr |
| Financing Cash Flow | - | 616.76 Cr | 42.41 Cr | 199.25 Cr | 261.39 Cr |
| Capital Expenditure | - | -15.39 Cr | -26.51 Cr | -10.34 Cr | -23.83 Cr |
| Free Cash Flow | - | -84.50 Cr | -455.70 Cr | -370.63 Cr | -262.60 Cr |
| Net Change in Cash | - | -64.06 L | 4.74 Cr | -3.38 Cr | -88.00 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 26.0% | -79.7% | -45.5% | 97.5% |
| Operating Margin % | - | -93.7% | -544.7% | -467.5% | 84.5% |
| Net Margin % | - | -93.2% | -512.6% | -477.2% | 82.7% |
| ROE % | - | -43.4% | -307.9% | 157.9% | 116.0% |
| ROCE % | - | -34.3% | -164.6% | 866.9% | 112.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPARC
Universal Music: Pershing Square Offer Highlights Company Value and Trades Cash for Dilution - Morningstar
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZjNVVlh5SzNhd0l6eFpDc0lvY2xybzJFT0RhRHltendtMVJRRjRQN3ZWOTcydUY4UUNFSUNoOU00X0RZOVZxQldKN3Nvb2ZobmU4N3ZEV0w3X2I3bVh6M1UxQ3BidHZ6bEViTFp1Sy01MzJuNUdXWEg0bTJSQmhzSnQ0MVFXV3A1UXF1WG…
Here's Why We're Watching Sparc Technologies' (ASX:SPN) Cash Burn Situation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQNnVXRjZscmZiQm9vanVrRGsxdjQ0YVNlY280V1BackhBVzhBSUpXRkZodVp2d1pCLXA1MmZWUThwUjdJXzZWS2h6a0xLSkoyeTFFaEx4Wk5uUTVhTXd4Q3ZaWFJLR25Xbmg1blUyV3hiRFp3c0RFSzRZNzRBd2kxMFlXc2dGTnFGN3AxZV…
Universal Music targeted in takeover bid by hedge fund Pershing Square - CBS News
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOZ0c2VzR1a0JWNzktVnRjcFBXMmNia19YSTZpTno2N0xWTVBCaGhKamRCbDhEZHpTTXY5cVE3emEwM0Fkdm5Sa2wyaDZENVU5ZmRUTEh3bEZQRDZPaHJPVnpFNEhXWGlkYTlqMVh1aTIxaE9nVzgyUzNIZW0tdUplQVJkZ244dHlXZW5qOV…
New SPARC AI deck details Overwatch push and global distribution - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPX21CWGMwWnZBcmw5U3hMNS1uRkJoOFJ5UGt2VHFHRHFLU2FkMms5TzlwZjV4SFd5T1pGbnA3MHJqNzZKNDJJLU40eE9EQ0xTaktvcTl5Z0EtV3Y1RFhmcDNUY1ZhaWNiSFAwLVBRZW9YRkZBUHdQa1J5ZmJBcUVZV0tGdFhVcERRYmZJX0…
Concerns Surrounding Sun Pharma Advanced Research's (NSE:SPARC) Performance - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPY0xhRDgwdE1sNV9JZ25NZE5lMGdaZUVSNHVuZlVQMlNJLVVjVmUxeWpNTDFBV0o4N05IZFI0dF93S1hYSnFpRTdYaGRYNWdBbFZtR3UwOUN2RTBwYWcwVWFoUEVSSVpmX1dEeERjdDlBTUNyY2dmZFZDZHdEZ2dSU1ZJbzZiSDUyUFh2dH…
This GPS Replacement Play Could Be Tapping Into a US$54 Billion Defense Shift - Streetwise Reports
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxORFN5WVRJVWFyb3NwZm44d1lpakVJNE8zd0h5VTFZeG0wNWdEaWpyQ29FMkIyal95Nm5rdWNpZlNuT05vODBsUEZ6Y2FRYmk5azVhcUxDYlZ3YXRjeFRsbW5MQ1lVSEY2RUQzRVlsbFN0YnVTSVY4ZHNucHpOSmxTRGpGTk9Kc3NHX2N2Tl…
SPARC — Frequently Asked Questions
What is the current share price of Sun Pharma Advanced Research Company Limited (SPARC)?
As of 2026-07-15 09:52 IST, Sun Pharma Advanced Research Company Limited (SPARC) trades at ₹254.80 on NSE. Its 52-week range is ₹108.71 to ₹277.57.
What is the market capitalisation of SPARC?
Sun Pharma Advanced Research Company Limited (SPARC) has a market capitalisation of ₹8,268.81 Cr on NSE.
What is the P/E ratio of SPARC?
SPARC trades at a trailing price-to-earnings (P/E) ratio of 5.32. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.29.
What is the return on equity (ROE) of SPARC?
SPARC has a return on equity (ROE) of 116.01%. Its return on capital employed (ROCE) is 112.03%.
Is SPARC a good stock to buy?
This page provides a data-driven analysis of Sun Pharma Advanced Research Company Limited (SPARC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.